Medscape | What's Hot at ASH 2013? Medscape This study directly compared the new agent obinutuzumab (Gazyva) against the standard therapy rituximab (Rituxan), and both were administered in combination with chlorambucil (abstract 6). Top-line results from this trial recently released by the ... |
